Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Multiple sclerosis and neuroimmunology

Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.

Patrick Schindler; Ulrike Grittner; Johanna Oechtering; David Leppert; Nadja Siebert; Ankelien S Duchow; Frederike C Oertel; Susanna Asseyer; Joseph Kuchling; Hanna G Zimmermann; Alexander U Brandt; Pascal Benkert; Markus Reindl; Sven Jarius; Friedemann Paul; Judith Bellmann-Strobl; Jens Kuhle; Klemens Ruprecht

Originally published in Journal of neuroinflammation · 2021-05-01

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Background Neuromyelitis optica spectrum disorder (NMOSD) is a frequently disabling neuroinflammatory syndrome with a relapsing course. Blood-based disease severity and prognostic biomarkers for NMOSD are a yet unmet clinical need. Here, we evaluated serum glial fibrillary acidic protein (sGFAP) and neurofilament light (sNfL) as disease severity and prognostic biomarkers in patients with aquaporin-4 immunoglobulin (Ig)G positive (AQP4-IgG + ) NMOSD. Methods sGFAP and sNfL were determined by single-molecule array technology in a prospective cohort of 33 AQP4-IgG + patients with NMOSD, 32 of which were in clinical remission at study baseline. Sixteen myelin oligodendrocyte glycoprotein IgG-positive (MOG-IgG + ) patients and 38 healthy persons were included as controls. Attacks were recorded in all AQP4-IgG + patients over a median observation period of 4.25 years. Results In patients with AQP4-IgG + NMOSD, median sGFAP (109.2 pg/ml) was non-significantly higher than in MOG-IgG + patients (81.1 pg/ml; p = 0.83) and healthy controls (67.7 pg/ml; p = 0.07); sNfL did not substantially differ between groups.

Discussion

The key results of this detailed analysis of sGFAP and sNfL measured by Simoa in a well-characterized cohort of AQP4-IgG+ and MOG-IgG+ patients, most of which were in clinical remission at study baseline, as well as in HC are (1) sGFAP levels of AQP4-IgG+ patients were just mildly and not significantly higher than those of MOG-IgG+ patients and HC, and sNFL levels did not substantially differ between groups. (2) However, remarkably, sGFAP was still clearly associated with parameters of clinical disability (EDSS, MSFC) in patients with AQP4-IgG+ NMOSD.

Conclusions

This study suggests a potential role for sGFAP as biomarker for disease severity and future disease activity in patients with AQP4-IgG+ NMOSD in phases of clinical remission. This is consistent with the pathophysiological concept of AQP4-IgG+ NMOSD being an immune-mediated astrocytopathy. The potential relevance of sGFAP as disease severity and prognostic biomarker in AQP4-IgG+ NMOSD thus warrants to be further explored in independent cohorts of AQP4-IgG+ patients with NMOSD.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?